Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A < 1.7 cM interval is responsible for Dmo1 obesity phenotypes in OLETF rats.
Watanabe TK, Okuno S, Yamasaki Y, Ono T, Oga K, Mizoguchi-Miyakita A, Miyao H, Suzuki M, Momota H, Goto Y, Shinomiya H, Hishigaki H, Hayashi I, Asai T, Wakitani S, Takagi T, Nakamura Y, Tanigami A. Watanabe TK, et al. Among authors: takagi t. Clin Exp Pharmacol Physiol. 2004 Jan-Feb;31(1-2):110-2. doi: 10.1111/j.1440-1681.2004.03959.x. Clin Exp Pharmacol Physiol. 2004. PMID: 14756694
Mutated G-protein-coupled receptor GPR10 is responsible for the hyperphagia/dyslipidaemia/obesity locus of Dmo1 in the OLETF rat.
Watanabe TK, Suzuki M, Yamasaki Y, Okuno S, Hishigaki H, Ono T, Oga K, Mizoguchi-Miyakita A, Tsuji A, Kanemoto N, Wakitani S, Takagi T, Nakamura Y, Tanigami A. Watanabe TK, et al. Among authors: takagi t. Clin Exp Pharmacol Physiol. 2005 May-Jun;32(5-6):355-66. doi: 10.1111/j.1440-1681.2005.04196.x. Clin Exp Pharmacol Physiol. 2005. PMID: 15854142
Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma.
Ishihara H, Fukuda H, Mizoguchi Y, Yamashita M, Aoki K, Ishiyama R, Ikeda T, Nemoto Y, Shimmura H, Hashimoto Y, Yoshida K, Hirai T, Iizuka J, Tokita D, Kondo T, Nagashima Y, Takagi T. Ishihara H, et al. Among authors: takagi t. Cancer Immunol Immunother. 2025 Jan 3;74(2):51. doi: 10.1007/s00262-024-03876-2. Cancer Immunol Immunother. 2025. PMID: 39751827 Free PMC article.
Tips for percutaneous nephrolithotomy for transplant kidney stone.
Yagisawa T, Shimizu T, Tachiki A, Ishiyama Y, Onohara T, Iida S, Ishida H, Takagi T. Yagisawa T, et al. Among authors: takagi t. IJU Case Rep. 2024 Oct 13;8(1):32-35. doi: 10.1002/iju5.12800. eCollection 2025 Jan. IJU Case Rep. 2024. PMID: 39749290 Free PMC article.
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.
Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T. Grünwald V, et al. Among authors: takagi t. Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35288. Online ahead of print. Int J Cancer. 2024. PMID: 39739622
3,102 results